Latest News
View AllAug 31, 2023
Gamida Cell to Present Corporate Highlights at the H.C. Wainwright 25th Annual Global Investment Conference
Read MoreAug 14, 2023
Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update
Read MoreAug 01, 2023
Gamida Cell to Report Second Quarter 2023 Financial Results
Read MoreJul 11, 2023
Data Published in Transplantation and Cellular Therapy Suggest Antiviral Protection After Transplantation with Gamida Cell’s Omisirge® (omidubicel-onlv)
Read MoreJun 14, 2023
Gamida Cell To Host Investor Day
Read MoreMay 31, 2023
Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
Read MoreMay 31, 2023
Data To Be Presented on Gamida Cell Natural Killer (NK) Cell Therapy Candidate GDA-201 at the International Society for Cell & Gene Therapy 2023 Annual Meeting
Read MoreMay 22, 2023
Gamida Cell Appoints Terry Coelho as CFO
Read MoreMay 15, 2023
Gamida Cell Reports First Quarter 2023 Financial Results and Provides Company Update
Read MoreMay 11, 2023
Gamida Cell Announces the Date of Its First Quarter 2023 Financial Results and Webcast
Read MoreApr 19, 2023
Gamida Cell Announces Pricing of $23 Million Public Offering of Securities
Read MoreApr 18, 2023
Gamida Cell Announces Launch of Public Offering of Securities
Read MoreApr 17, 2023
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
Read MoreMar 27, 2023
Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update
Read MoreMar 20, 2023
Gamida Cell Announces Changes to Board of Directors
Read MoreMar 20, 2023
Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast
Read MoreMar 07, 2023
Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference
Read MoreFeb 18, 2023
Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR
Read MoreDec 12, 2022
Gamida Cell Announces Closing of $25 Million Financing With Highbridge
Read MoreNov 23, 2022
Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
Read MoreNov 21, 2022
Gamida Cell Provides Regulatory Update on Omidubicel
Read MoreNov 14, 2022
Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update
Read MoreNov 10, 2022
Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference
Read MoreNov 07, 2022
GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers
Read MoreNov 07, 2022
Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast
Read MoreNov 03, 2022
Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting
Read MoreOct 10, 2022
Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa
Read MoreSep 29, 2022
Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting
Read MoreSep 28, 2022
Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares
Read MoreSep 28, 2022
Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing
Read MoreSep 27, 2022
Gamida Cell Announces Launch of Public Offering of Ordinary Shares
Read MoreSep 19, 2022
Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies
Read MoreSep 12, 2022
Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting
Read MoreAug 15, 2022
Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update
Read MoreAug 10, 2022
Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
Read MoreAug 08, 2022
Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast
Read MoreAug 01, 2022
Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
Read MoreJun 13, 2022
Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference
Read MoreJun 10, 2022
Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors
Read MoreJun 02, 2022
Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
Read MoreJun 01, 2022
Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
Read MoreJun 01, 2022
Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
Read MoreMay 17, 2022
Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference
Read MoreMay 10, 2022
Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update
Read MoreMay 05, 2022
Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022
Read MoreMay 03, 2022
Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast
Read MoreApr 27, 2022
Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
Read MoreApr 26, 2022
Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201
Read MoreApr 25, 2022
Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
Read MoreApr 25, 2022
Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
Read MoreApr 07, 2022
Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference
Read MoreMar 15, 2022
Gamida Cell Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
Read MoreMar 10, 2022
Gamida Cell to Present Corporate Highlights at the Oppenheimer 32nd Annual Healthcare Conference
Read MoreMar 08, 2022
Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results and Webcast
Read MoreFeb 09, 2022
Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel
Read MoreJan 31, 2022
Gamida Cell Announces Appointment of Anat Cohen-Dayag and Naama Halevi-Davidov to its Board of Directors
Read MoreJan 31, 2022
Gamida Cell Provides Key Program Updates and 2022 Financial Guidance
Read MoreJan 19, 2022
Gamida Cell Provides Update on Omidubicel BLA Submission
Read MoreJan 07, 2022
Gamida Cell Announces Data to be Presented at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
Read MoreDec 13, 2021
Gamida Cell Presents Two-Year Survival Data for GDA-201 and Resource Utilization Analysis for Omidubicel at 63rd ASH Annual Meeting
Read MoreDec 11, 2021
Gamida Cell Presents New Omidubicel Data at 63rd ASH Annual Meeting
Read MoreNov 16, 2021
Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
Read MoreNov 15, 2021
Gamida Cell Reports Third Quarter 2021 Financial Results and Provides Company Update
Read MoreNov 11, 2021
Gamida Cell Provides Update on Pre-BLA Meeting With FDA for Omidubicel
Read MoreNov 09, 2021
Gamida Cell Presents New Data on Nicotinamide-Enabled NK Cell Therapy at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
Read MoreNov 08, 2021
Gamida Cell Announces the Date of Its Third Quarter 2021 Financial Results and Webcast
Read MoreNov 04, 2021
Gamida Cell Announces Data to Be Presented at 63rd ASH Annual Meeting
Read MoreNov 04, 2021
Gamida Cell Presents Data on its NAM-Enabled NK Cell Therapies at Protein & Antibody Engineering Summit (PEGS) Europe
Read MoreOct 26, 2021
Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today’s Virtual R&D Day
Read MoreOct 19, 2021
Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
Read MoreSep 28, 2021
Gamida Cell to Host Virtual Event Highlighting GDA-201 and NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline
Read MoreSep 02, 2021
Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in September
Read MoreAug 11, 2021
Gamida Cell Reports Second Quarter 2021 Financial Results and Provides Company Update
Read MoreAug 04, 2021
Gamida Cell Announces the Date of Its Second Quarter 2021 Financial Results and Webcast
Read MoreAug 03, 2021
Gamida Cell to Present at the BTIG Virtual Biotechnology Conference
Read MoreJun 23, 2021
Gamida Cell Announces Publication in Blood, the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy (Omidubicel) for Patients with Blood Cancer who Require an Allogeneic Stem Cell Transplant
Read MoreJun 09, 2021
Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in June
Read MoreJun 07, 2021
Gamida Cell Announces Appointment of Senior Vice President, Global Operations and Manufacturing and Provides Commercial Manufacturing Update
Read MoreMay 12, 2021
Gamida Cell to Present at the RBC Capital Markets Global Healthcare Conference
Read MoreMay 11, 2021
Gamida Cell Reports First Quarter 2021 Financial Results and Provides Company Update
Read MoreMay 04, 2021
Gamida Cell Announces the Date of Its First Quarter 2021 Financial Results and Webcast
Read MoreApr 07, 2021
Gamida Cell to Present at the 20th Annual Needham Virtual Healthcare Conference
Read MoreMar 15, 2021
Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Read MoreMar 09, 2021
Gamida Cell Reports Full Year 2020 Financial Results and Provides Company Update
Read MoreMar 03, 2021
Gamida Cell to Present at Upcoming Investor Conferences
Read MoreMar 02, 2021
Gamida Cell Announces the Date of Its Full Year 2020 Financial Results and Webcast
Read MoreMar 01, 2021
Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Read MoreFeb 16, 2021
Gamida Cell Announces $75 Million Financing with Highbridge Capital Management
Read MoreFeb 09, 2021
Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of ASTCT and CIBMTR
Read MoreJan 11, 2021
Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
Read MoreJan 05, 2021
Gamida Cell to Present at Upcoming January Investor Conferences
Read MoreDec 21, 2020
Gamida Cell Announces Closing of $75 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Read MoreDec 18, 2020
Gamida Cell Added to NASDAQ Biotechnology Index
Read MoreDec 17, 2020
Gamida Cell Announces Pricing of $65 Million Public Offering of Ordinary Shares
Read MoreDec 16, 2020
Gamida Cell Announces Launch of Public Offering of Ordinary Shares
Read MoreDec 14, 2020
Gamida Cell Provides Regulatory Update on Biologics License Application for Omidubicel
Read MoreDec 09, 2020
Gamida Cell Provides Pipeline Update, Including Detailed Results of Pivotal Phase 3 Clinical Study of Omidubicel, and Prepares to Start BLA Submission by End of 2020
Read MoreDec 05, 2020
Gamida Cell Presents Updated, Expanded Results from Phase 1 Study of Natural Killer Cell Therapy GDA-201 at ASH Annual Meeting and Exposition
Read MoreDec 02, 2020
Gamida Cell to Host Virtual Pipeline Deep Dive
Read MoreNov 24, 2020
Gamida Cell to Present at Upcoming Conferences
Read More@GAMIDACELLTX
Patient focus
We put the needs and experiences of patients at the core of our mission and purpose, working to turn cells into powerful therapeutics.
Future of cancer care
Our proprietary nicotinamide (NAM) technology leverages the properties of NAM to enhance and expand cells, creating allogeneic cell therapy products and candidates that are potentially curative for patients with hematologic malignancies.
Dedicated team
We are pioneers with respected track records in cell therapy research and development, manufacturing and commercialization. We combine bold and creative pursuits in science with a passion for curing cancer so that patients can live longer, better lives.
